Boston will inherit products, including Penumbra’s Lightning thrombectomy systems, to advance its vascular care provision.
Boston Scientific Corporation will acquire Penumbra for $14.5B in cash and stock, aiming to close the deal this year. BSX expands into high-growth neurovascular and peripheral thrombectomy segments, ...